Janus Henderson Group PLC Grows Holdings in Xeris Biopharma Holdings, Inc. $XERS

Janus Henderson Group PLC lifted its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 322.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 295,489 shares of the company’s stock after acquiring an additional 225,602 shares during the quarter. Janus Henderson Group PLC’s holdings in Xeris Biopharma were worth $1,713,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in XERS. California State Teachers Retirement System raised its position in Xeris Biopharma by 19.3% in the first quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock valued at $1,046,000 after purchasing an additional 29,168 shares during the period. Royal Bank of Canada lifted its stake in Xeris Biopharma by 12.9% during the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after purchasing an additional 4,974 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Xeris Biopharma by 59.0% during the first quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock worth $422,000 after buying an additional 27,003 shares during the period. Quantinno Capital Management LP grew its stake in shares of Xeris Biopharma by 25.4% in the first quarter. Quantinno Capital Management LP now owns 30,971 shares of the company’s stock valued at $180,000 after buying an additional 6,275 shares in the last quarter. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Xeris Biopharma in the first quarter valued at $1,456,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ:XERS opened at $7.93 on Monday. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $10.08. The company’s 50 day moving average is $7.68 and its two-hundred day moving average is $6.79. The company has a market cap of $1.37 billion, a PE ratio of -72.09 and a beta of 0.66. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). The firm had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%. Equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Insider Buying and Selling

In other news, insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $8.01, for a total value of $133,494.66. Following the transaction, the insider owned 1,144,462 shares in the company, valued at approximately $9,167,140.62. This represents a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John Johnson sold 15,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $91,350.00. Following the sale, the director directly owned 683,083 shares in the company, valued at $4,159,975.47. This trade represents a 2.15% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 266,499 shares of company stock valued at $1,996,417 over the last 90 days. 4.35% of the stock is currently owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.